Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of ANAWIDOW in Healthy Adults
NCT04848714Phase 1Completed
- Sponsor
- Laboratorios Silanes
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Antivenin (Latrodectus mactans) in latrodectism, sponsored by Laboratorios Silanes. Primary endpoints: Maximum Observed Concentration at Day 21, Area Under the Curve from Time Zero to Last Measurable Concentration at 21 days and 6 more. Started Jul 2021; status: completed.
02
Drugs
Antivenin (Latrodectus mactans)
03
Conditions
latrodectism
Beyond the preview
Go deeper on NCT04848714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848714.